Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including breast cancer. This growing body of evidence reflects Natera's ongoing investment in clinical research.
Susan G. Komen is the only advocacy organization addressing breast cancer through a comprehensive approach that spans research, community health, patient support, public policy, and global outreach. The partnership complements Natera’s commitment to advancing evidence generation in breast cancer, with multiple ongoing and planned studies evaluating how MRD testing may help personalize care, inform treatment decisions, and improve outcomes.
